rs3211867 — CD36

CD36 and the Fat Sensor You Never Knew You Had

Before a single drop of dietary fat reaches your bloodstream, your body is already preparing for it. CD36 — the fatty acid translocase — sits on the surface of taste bud cells, intestinal enterocytes, and dozens of other cell types, acting as the primary sensor and gatekeeper for long-chain dietary fats. rs3211867 is an intronic variant in the CD36 gene that reduces how much of this protein is produced, with measurable downstream effects on postprandial lipid handling and circulating CD36 levels.

The Mechanism

CD36 operates simultaneously in at least three contexts relevant to lipid metabolism. In circumvallate taste buds¹¹ In circumvallate taste buds
CD36 initiates fat taste perception and the cephalic phase of digestion, triggering anticipatory digestive signals before fat even enters the gut. In intestinal enterocytes, CD36 binds long-chain fatty acids and facilitates their packaging into chylomicrons — the lipid particles that transport dietary fat through the lymph into the bloodstream. In macrophages, CD36 mediates uptake of oxidized LDL and modulates pro-inflammatory signaling²² pro-inflammatory signaling
CD36 in macrophages drives foam cell formation; reduced expression is locally protective.

rs3211867 is a C→A substitution in intron 3 of the CD36 gene. Like several other CD36 intronic variants, it functions as an [expression quantitative trait locus (eQTL) | eQTL: a genetic variant that influences how much mRNA/protein a gene produces, without changing the protein sequence itself], influencing CD36 transcription — likely through altered chromatin accessibility or methylation susceptibility at regulatory elements near intron 3. The A allele is associated with greater CD36 promoter methylation and lower CD36 mRNA and protein output. Circulating soluble CD36 (sCD36) — shed from cell surfaces and measurable in plasma — drops significantly in A allele carriers compared to CC homozygotes in healthy controls (p = 0.02)³³ in healthy controls (p = 0.02)
Toure et al. BMC Medical Genomics 2022, PMID 36031603.

The Evidence

Toure et al. (2022)⁴⁴ Toure et al. (2022) examined 100 Senegalese women (50 controls, 50 with type 2 diabetes). In healthy controls, CC genotype carriers had significantly higher sCD36 levels than AA/AC carriers (3,889 vs 1,745 pg/mL; p = 0.02). Lower sCD36 correlated inversely with HDL-cholesterol (r = −0.52, p = 0.0001) and triglycerides, suggesting that reduced CD36 function, while potentially reducing macrophage ox-LDL uptake, impairs postprandial lipid clearance.

Love-Gregory et al. (2016)⁵⁵ Love-Gregory et al. (2016) studied 1,117 participants and demonstrated that CD36 promoter variants and methylation sites that reduce CD36 expression associate with higher chylomicron remnant concentrations and elevated LDL particle numbers after meals — a pattern consistent with slowed postprandial lipid clearance. Multiple CD36 variants reducing CD36 protein expression in monocytes correlated protectively with HDL and VLDL fractions, while other variants affecting intestinal CD36 worsened postprandial hypertriglyceridemia.

The picture is complex: reducing CD36 in macrophages is atherogenic-protective (less oxidized-LDL uptake, less foam cell formation), but reducing CD36 in enterocytes worsens [postprandial hypertriglyceridemia | elevated blood triglycerides in the hours after eating, associated with cardiovascular risk]. rs3211867's net effect appears to tilt toward impaired postprandial clearance, raising chylomicron remnants and LDL particles after fat-containing meals.

An early study by Bokor et al. (2010)⁶⁶ Bokor et al. (2010) reported OR = 1.96 for early-onset obesity in European adolescents carrying the A allele. However, a subsequent meta-analysis in 9,973 European subjects found no significant obesity association (Choquet et al. 2011, PMID 20966904⁷⁷ Choquet et al. 2011, PMID 20966904), limiting confidence in the obesity link specifically.

Practical Actions

The most actionable consequence of reduced CD36 function is impaired postprandial fat handling. A meal containing large amounts of saturated and long-chain fatty acids may generate a larger and more prolonged chylomicron remnant response. Favoring dietary fats that bypass intestinal CD36-mediated packaging — medium-chain triglycerides (MCTs) and omega-3 fatty acids from marine sources (EPA and DHA), which are absorbed more efficiently through alternative pathways — can help blunt this postprandial surge.

Fat taste sensitivity may also be modestly reduced. This can influence dietary fat intake subconsciously; tracking dietary fat quantitatively (rather than relying on palatability cues) is advisable to avoid gradual fat creep.

Monitoring postprandial lipids — specifically a non-fasting triglyceride or lipoprotein particle count — gives a truer picture of cardiovascular risk for CD36 reduced-expression variants than fasting lipids alone, since the impairment manifests primarily after meals.

Interactions

rs3211867 is in partial linkage disequilibrium with rs1761667 (the most-studied CD36 promoter variant) and rs3211938 (a coding variant that produces a truncated, unstable CD36 protein). Individuals carrying A alleles at both rs3211867 and rs1761667 would be expected to have compounded reduction in CD36 expression through independent regulatory pathways — methylation-related eQTL effects (rs3211867) plus promoter activity reduction (rs1761667). A compound action covering this combination may be warranted if literature evidence for the combined effect is found.